To further assess whether the BRAF mutation status affects CRC cell viability after AZ304 treatment, anti-proliferative effects of AZ304 were determined against four CRC cell lines, including two V600E mutant (RKO and HT-29) and two wild type (DiFi and Caco-2) BRAF cell lines, respectively. The gene discussed is BRAF; the disease is colorectal carcinoma.